CAR-T and other advanced therapies hold transformative, and even curative potential, however reimbursement bottlenecks are preventing widespread access. Payer hesitation, regulatory complexity, and other issues have left many patients unable to receive treatment. To ensure sustainable commercial success and equitable patient access, new reimbursement models and policy innovation is required. This session will feature experts from payer organizations, policymakers, and pharma leaders to explore the most pressing financial barriers to CAR-T adoption and innovative solutions to overcome them. Key topics include: • Innovative Payment Models: Examining value-based agreements, risk-sharing models, and alternative financing mechanisms. • The Future of Payer Engagement: How insurers, CMS, and private payers are adapting to support cell and gene therapy reimbursement. This discussion will demystify the complexities of reimbursement, giving attendees actionable insights to improve market access strategies and patient outcomes.